Skip to main content

Turn Therapeutics Inc.

corporate_fare Company Profile

Turn Therapeutics Inc.

TTRX·NASDAQ·Life Sciences·CIK 0002023016

Turn Therapeutics develops non-systemic, non-biologic topical immunomodulators for inflammatory skin diseases. The company's primary focus is its lead program, GX-03, which is being studied for moderate-to-severe eczema. This research is based on preclinical evidence showing it can inhibit cytokines and reduce eczema severity, alongside a favorable real-world tolerability record from its prior use in cleared medical device indications. GX-03 is currently in an ongoing, randomized, double-blind, vehicle-controlled clinical study for moderate-to-severe eczema, with an interim assessment planned at approximately 50% trial completion. Topline results are expected mid-2026. In addition to eczema, GX-03 is being developed for onychomycosis, supported by in-vivo data demonstrating nail penetration and antifungal activity. The company's historical medical device portfolio, including K183681, K160872, and K171191, provides background tolerability and feasibility experience with the formula. K183681 has been licensed to Medline under a license and supply agreement. Turn Therapeutics is seeking new drug approvals for the GX-03 formula, which includes polyhexanide ("PHMB"), as a treatment for both eczema and onychomycosis. PHMB is a well-characterized polymer with strong antimicrobial, anti-inflammatory, and immunomodulating properties, and an established safety profile. The company also conducts exploratory work on a thermostable intranasal vaccine platform, but this is not part of its primary dermatology development path.

Turn Therapeutics Inc. (NASDAQ:TTRX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 31 items for TTRX at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Turn Therapeutics Publishes Peer-Reviewed Data for Lead Atopic Dermatitis Candidate GX-03
  • Former FDA Commissioner Dr. Stephen M. Hahn Appointed Executive Clinical and Regulatory Lead
  • Turn Therapeutics Reports Q1 Results: Cash Up, Runway Extended Amidst Going Concern
  • Turn Therapeutics Reports Q1 Results, Boosts Cash to $11.2M, Addresses Going Concern
  • Turn Therapeutics Discloses Going Concern Doubt, Secures $25M Loan, and Faces Significant Dilution Risk

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$3.19M
Diluted EPS
-$0.12
Op. Cash Flow
-$2.56M
Operating Income
-$5.86M
Cash & Equivalents
$4.03M
Debt / Equity
0.00×
Shares Outstanding
29.45M sh
Source: 10-K · filed 2026-03-31 · accession 0001213900-26-037505
$8 -1.14% today
52-week range · as of 2026-11-16 $2.57 – $16.45
Market cap
$247.49M
Volume
82.8K (0.9× avg)
3-mo avg 95K
Live data · 2026-11-22 12:47 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed TTRX - Filings & News (Page 2)

TTRX
May 27, 2026, 8:10 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $5.37
Real-time Price: $8.00 info
Change: +$2.63 (+49%) info
Market Cap: $247.486M info
TTRX
May 18, 2026, 8:15 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.12
Real-time Price: $8.00 info
Change: +$3.88 (+94%) info
Market Cap: $247.486M info
TTRX
May 11, 2026, 4:17 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $3.78
Real-time Price: $8.00 info
Change: +$4.22 (+112%) info
Market Cap: $247.486M info
TTRX
May 11, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.92
Real-time Price: $8.00 info
Change: +$4.08 (+104%) info
Market Cap: $247.486M info
TTRX
Mar 31, 2026, 4:30 PM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $3.20
Real-time Price: $8.00 info
Change: +$4.80 (+150%) info
Market Cap: $247.486M info
TTRX
Mar 31, 2026, 4:18 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.20
Real-time Price: $8.00 info
Change: +$4.80 (+150%) info
Market Cap: $247.486M info
TTRX
Mar 24, 2026, 8:17 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.42
Real-time Price: $8.00 info
Change: +$4.58 (+134%) info
Market Cap: $247.486M info
TTRX
Feb 17, 2026, 8:10 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.50
Real-time Price: $8.00 info
Change: +$4.50 (+129%) info
Market Cap: $247.486M info
TTRX
Feb 09, 2026, 8:44 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.81
Real-time Price: $8.00 info
Change: +$4.19 (+110%) info
Market Cap: $247.486M info
TTRX
Jan 12, 2026, 8:12 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.60
Real-time Price: $8.00 info
Change: +$3.40 (+74%) info
Market Cap: $247.486M info
TTRX
Jan 07, 2026, 4:18 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.57
Real-time Price: $8.00 info
Change: +$3.43 (+75%) info
Market Cap: $247.486M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets